NCT01009242View on ClinicalTrials.gov

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
ArthritisRheumatoid Arthritis
Interventions
BIOLOGICAL

CDP6038

"Single dose:~1 mg/kg CDP6038 IV"

BIOLOGICAL

CDP6038

"Single dose:~0.1mg/kg CDP6038 IV"

BIOLOGICAL

CDP6038

"Single dose:~1.0mg/kg CDP6038 SC"

OTHER

Placebo IV

"Single dose:~Placebo IV"

OTHER

Placebo SC

"Single dose:~Placebo SC"

DRUG

CDP 6038 SC

Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo

DRUG

Methotrexate

Individual stable doses of methotrexate.

Trial Locations (6)

Unknown

Duncansville

Dallas

San Antonio

Berlin

Cologne

Erlangen

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT01009242 - To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate | Biotech Hunter | Biotech Hunter